Cargando…

Neutropenia and Infection Prophylaxis in Childhood Cancer

PURPOSE OF REVIEW: Pediatric oncology patients frequently experience episodes of prolonged neutropenia which puts them at high risk for infection with significant morbidity and mortality. Here, we review the data on infection prophylaxis with a focus on both pharmacologic and ancillary interventions...

Descripción completa

Detalles Bibliográficos
Autores principales: Villeneuve, Stephanie, Aftandilian, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885776/
https://www.ncbi.nlm.nih.gov/pubmed/35230594
http://dx.doi.org/10.1007/s11912-022-01192-5
_version_ 1784660514911027200
author Villeneuve, Stephanie
Aftandilian, Catherine
author_facet Villeneuve, Stephanie
Aftandilian, Catherine
author_sort Villeneuve, Stephanie
collection PubMed
description PURPOSE OF REVIEW: Pediatric oncology patients frequently experience episodes of prolonged neutropenia which puts them at high risk for infection with significant morbidity and mortality. Here, we review the data on infection prophylaxis with a focus on both pharmacologic and ancillary interventions. This review does not include patients receiving hematopoietic stem cell transplantation. RECENT FINDINGS: Patients with hematologic malignancies are at highest risk for infection. Bacterial and fungal prophylaxis decrease the risk of infection in certain high-risk groups. Ancillary measures such as ethanol locks, chlorhexidine gluconate baths, GCSF, IVIG, and mandatory hospitalization do not have enough data to support routine use. There is limited data on risk of infection and role of prophylaxis in patients receiving immunotherapy and patients with solid tumors. Patients with Down syndrome and adolescent and young adult patients may benefit from additional supportive care measures and protocol modifications. SUMMARY: Consider utilizing bacterial and fungal prophylaxis in patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. More research is needed to evaluate other supportive care measures and the role of prophylaxis in patients receiving immunotherapy.
format Online
Article
Text
id pubmed-8885776
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-88857762022-03-01 Neutropenia and Infection Prophylaxis in Childhood Cancer Villeneuve, Stephanie Aftandilian, Catherine Curr Oncol Rep Pediatric Oncology (KL Davis, Section Editor) PURPOSE OF REVIEW: Pediatric oncology patients frequently experience episodes of prolonged neutropenia which puts them at high risk for infection with significant morbidity and mortality. Here, we review the data on infection prophylaxis with a focus on both pharmacologic and ancillary interventions. This review does not include patients receiving hematopoietic stem cell transplantation. RECENT FINDINGS: Patients with hematologic malignancies are at highest risk for infection. Bacterial and fungal prophylaxis decrease the risk of infection in certain high-risk groups. Ancillary measures such as ethanol locks, chlorhexidine gluconate baths, GCSF, IVIG, and mandatory hospitalization do not have enough data to support routine use. There is limited data on risk of infection and role of prophylaxis in patients receiving immunotherapy and patients with solid tumors. Patients with Down syndrome and adolescent and young adult patients may benefit from additional supportive care measures and protocol modifications. SUMMARY: Consider utilizing bacterial and fungal prophylaxis in patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. More research is needed to evaluate other supportive care measures and the role of prophylaxis in patients receiving immunotherapy. Springer US 2022-03-01 2022 /pmc/articles/PMC8885776/ /pubmed/35230594 http://dx.doi.org/10.1007/s11912-022-01192-5 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Pediatric Oncology (KL Davis, Section Editor)
Villeneuve, Stephanie
Aftandilian, Catherine
Neutropenia and Infection Prophylaxis in Childhood Cancer
title Neutropenia and Infection Prophylaxis in Childhood Cancer
title_full Neutropenia and Infection Prophylaxis in Childhood Cancer
title_fullStr Neutropenia and Infection Prophylaxis in Childhood Cancer
title_full_unstemmed Neutropenia and Infection Prophylaxis in Childhood Cancer
title_short Neutropenia and Infection Prophylaxis in Childhood Cancer
title_sort neutropenia and infection prophylaxis in childhood cancer
topic Pediatric Oncology (KL Davis, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885776/
https://www.ncbi.nlm.nih.gov/pubmed/35230594
http://dx.doi.org/10.1007/s11912-022-01192-5
work_keys_str_mv AT villeneuvestephanie neutropeniaandinfectionprophylaxisinchildhoodcancer
AT aftandiliancatherine neutropeniaandinfectionprophylaxisinchildhoodcancer